HC Wainwright Expects Stronger Earnings for Kodiak Sciences

Kodiak Sciences Inc. (NASDAQ:KOD) – HC Wainwright boosted their FY2025 earnings per share (EPS) estimates for Kodiak Sciences in a report released on Thursday, January 22nd. HC Wainwright analyst M. Caufield now forecasts that the company will earn ($4.29) per share for the year, up from their previous forecast of ($4.35). HC Wainwright currently has a “Buy” rating and a $38.00 target price on the stock. The consensus estimate for Kodiak Sciences’ current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences’ Q4 2025 earnings at ($1.02) EPS, Q1 2026 earnings at ($0.75) EPS, Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.80) EPS, Q4 2026 earnings at ($0.84) EPS, FY2026 earnings at ($3.13) EPS, FY2027 earnings at ($3.30) EPS, FY2028 earnings at ($2.33) EPS and FY2029 earnings at ($0.57) EPS.

Kodiak Sciences (NASDAQ:KOD) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($1.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.07) by ($0.09).

Other research analysts have also recently issued reports about the stock. Wall Street Zen cut shares of Kodiak Sciences from a “hold” rating to a “sell” rating in a report on Saturday, October 11th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Kodiak Sciences in a research report on Thursday. Lifesci Capital began coverage on Kodiak Sciences in a research note on Thursday, October 23rd. They set an “outperform” rating and a $40.00 target price for the company. JPMorgan Chase & Co. raised Kodiak Sciences from a “neutral” rating to an “overweight” rating and raised their price target for the company from $15.00 to $24.00 in a report on Friday, October 24th. Finally, UBS Group initiated coverage on Kodiak Sciences in a research note on Wednesday, January 7th. They issued a “buy” rating and a $50.00 price target on the stock. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $28.29.

Kodiak Sciences Stock Performance

KOD stock opened at $25.86 on Monday. The stock has a market capitalization of $1.37 billion, a PE ratio of -6.28 and a beta of 2.67. The company has a fifty day moving average of $25.40 and a 200-day moving average of $16.62. Kodiak Sciences has a one year low of $1.92 and a one year high of $31.18.

Institutional Investors Weigh In On Kodiak Sciences

A number of institutional investors and hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets increased its stake in Kodiak Sciences by 89.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 6,373 shares of the company’s stock valued at $104,000 after purchasing an additional 3,009 shares in the last quarter. Diversified Trust Co. acquired a new stake in Kodiak Sciences in the fourth quarter valued at $219,000. Headlands Technologies LLC grew its holdings in Kodiak Sciences by 256.4% in the second quarter. Headlands Technologies LLC now owns 8,083 shares of the company’s stock valued at $30,000 after purchasing an additional 5,815 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in shares of Kodiak Sciences in the third quarter valued at $204,000. Finally, SG Americas Securities LLC acquired a new position in shares of Kodiak Sciences during the 3rd quarter worth $228,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Insider Transactions at Kodiak Sciences

In related news, Director Bros. Advisors Lp Baker purchased 2,608,696 shares of Kodiak Sciences stock in a transaction dated Thursday, December 18th. The stock was bought at an average cost of $23.00 per share, for a total transaction of $60,000,008.00. Following the transaction, the director owned 18,358,772 shares in the company, valued at approximately $422,251,756. The trade was a 16.56% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 45.90% of the company’s stock.

Kodiak Sciences News Roundup

Here are the key news stories impacting Kodiak Sciences this week:

• Positive Sentiment: HC Wainwright raised its Q4 2025 and FY2025 EPS estimates slightly (Q4 2025: from ($1.07) to ($1.02); FY2025: from ($4.35) to ($4.29)), and materially improved its FY2029 loss forecast (from ($0.82) to ($0.57)). These changes modestly tighten longer‑range expectations and could be seen as evidence of gradual improvement further out.
• Neutral Sentiment: Analysts published FY2030 forecasts for Kodiak that extend the modeling horizon but contain no immediate operational updates; long‑range projections often have limited short‑term trading impact. Read More.
• Negative Sentiment: HC Wainwright cut multiple near‑term estimates across 2026 and beyond: Q1–Q3 2026 EPS were lowered (Q1 to ($0.75) from ($0.68); Q2 to ($0.76) from ($0.70); Q3 to ($0.80) from ($0.73)); Q4 2026 was also trimmed to ($0.84). FY2026 was reduced to ($3.13) from ($2.88), and FY2027/FY2028 were also adjusted downward. The cluster of downward revisions increases uncertainty around near‑term cash burn and milestones, which is likely the main pressure on the stock today.

Kodiak Sciences Company Profile

Kodiak Sciences, Inc is a clinical‐stage biopharmaceutical company headquartered in Palo Alto, California, that focuses on the discovery and development of novel therapies for retinal diseases. The company’s proprietary technology centers on antibody biopolymer conjugates (ABCs), which are designed to extend durability, enhance tissue penetration and improve the safety profile of existing therapeutic modalities. Kodiak’s research and development efforts target conditions such as wet age-related macular degeneration (wet AMD), diabetic macular edema (DME) and other serious ophthalmic disorders.

The lead product candidate in Kodiak’s pipeline is KSI-301, an anti-VEGF antibody biopolymer conjugate administered via intravitreal injection.